• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

PRT-060318

CAS No. 1194961-19-7

PRT-060318 ( PRT060318 | PRT 060318 | PRT-060318 | PRT318 )

产品货号. M17182 CAS No. 1194961-19-7

PRT-060318 (PRT318) 是一种新型选择性 Syk 酪氨酸激酶抑制剂,可作为 HIT 治疗的一种方法。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥389 有现货
5MG ¥697 有现货
10MG ¥1110 有现货
25MG ¥2333 有现货
50MG ¥3969 有现货
100MG ¥5792 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    PRT-060318
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    PRT-060318 (PRT318) 是一种新型选择性 Syk 酪氨酸激酶抑制剂,可作为 HIT 治疗的一种方法。
  • 产品描述
    PRT-060318, also known as PRT318 or P142–76, is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment. PRT318 completely inhibited HIT immune complex-induced aggregation of both human and transgenic HIT mouse platelets. Transgenic HIT model mice were treated with KKO, a mouse monoclonal HIT-like antibody, and heparin. The experimental group received orally dosed PRT318, whereas the control group received vehicle. Nadir platelet counts of PRT318-treated mice were significantly higher than those of control mice. When examined with a novel thrombosis visualization technique, mice treated with PRT318 had significantly reduced thrombosis.
  • 体外实验
    PRT318 is a potent inhibitor of purified Syk kinase with an IC50 of 4 nM. Syk kinase is inhibited by 92%, whereas all other kinases retains more than 70% at a concentration of 50 nM of PRT318. PRT318 and P505-15 effectively antagonize CLL cell survival after B-cell receptor (BCR) triggering and in nurse-like cell-co-cultures. They inhibit BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT318 and P505-15 inhibit Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering.
  • 体内实验
    PRT318 completely inhibits HIT immune complex-induced aggregation of both human and transgenic HIT mouse platelets. Pretreatment of mice with PRT318 markedly reduces HIT IC-induced thrombosis in the lungs. The Thrombosis Score is significantly lower for PRT318-treated mice compared with control.
  • 同义词
    PRT060318 | PRT 060318 | PRT-060318 | PRT318
  • 通路
    PI3K/Akt/mTOR signaling
  • 靶点
    mTOR
  • 受体
    Syk
  • 研究领域
    Cancer|Inflammation/Immunology
  • 适应症
    ——

化学信息

  • CAS Number
    1194961-19-7
  • 分子量
    449.81
  • 分子式
    C18H24N6O·3HCl
  • 纯度
    >98% (HPLC)
  • 溶解度
    H2O : 5.6 mg/mL. 16.45 mM;
  • SMILES
    CC1=CC(=CC=C1)NC2=NC(=NC=C2C(=O)N)N[C@@H]3CCCC[C@@H]3N
  • 化学全称
    2-(((1R,2S)-2-aminocyclohexyl)amino)-4-(m-tolylamino)pyrimidine-5-carboxamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

产品手册
关联产品
  • CC-115 hydrochloride

    一种新型 mTOR 和 DNA-PK 双重抑制剂,IC50 分别为 21 nM 和 13 nM。

  • JR-AB2-011

    JR-AB2-011 通过阻断 Rictor-mTOR 关联来抑制 mTORC2 活性(Ki:0.19 μM)。 JR-AB2-011 具有抗多形性胶质母细胞瘤 (GBM) 特性。

  • DMH-25

    DMH25是一种新型共价有效的mTOR抑制剂,对三阴性乳腺癌细胞表现出体内抗肿瘤活性。在体内,DHM25是三阴性乳腺癌细胞生长和转移的有效抑制剂,为其临床应用铺平了道路。在肿瘤学中的应用。